Significance of HER2 Low-Level Copy Gain in Barrett s Cancer: Implications for Fluorescence In situ Hybridization Testing intissues

Transcription

1 Imaging, Diagnosis, Prognosis Significance of HER2 Low-Level Copy Gain in Barrett s Cancer: Implications for Fluorescence In situ Hybridization Testing intissues Sandra Rauser, 1,4 Roland Weis, 3 Herbert Braselmann, 2 Marcus Feith, 4 Hubert J. Stein, 6 Rupert Langer, 5 Peter Hutzler, 1 Michael Hausmann, 7 Silke Lassmann, 3 Jo«rg Ru«diger Siewert, 4 Heinz Ho«fler, 1,5 Martin Werner, 3 and Axel Walch 1 Abstract Purpose: HER2 may be a relevant biomarker in Barrett s cancer. We compared three HER2 laboratory methods, standard fluorescence in situ hybridization (FISH), image-based threedimensional FISH in thick (16 Am) sections, and immunohistochemistry, to predict patient outcome. Experimental Design: Tissue microarray sections from 124 Barrett s cancer patients were analyzed by standard FISH on thin (4 Am) sections and by image-based three-dimensional FISH on thick (16 Am) sections for HER2 and chromosome-17, as well for p185 HER2 by immunohistochemistry. Correlations with clinical and follow-up data were examined. Results: Only three-dimensional FISH on thick (16 Am) sections revealed HER2 gene copy gain to be associated with increased disease-specific mortality (relative risk, 2.1; 95% confidence interval, ; P = 0.033). In contrast, standard FISH on thin (4 Am) sections and immunohistochemistry failed to predict clinical outcome. Low-level gain of HER2 occurred frequently in Barrett s cancer (z HER2 copies, 59.7%; HER2-to-chromosome-17 ratio, z ; 61.2%) and defined a subpopulation for patient outcome as unfavorable as HER2 gene amplification [disease-free survival, P = (HER2 copies)]. This low-level group was neither definable by standard FISH nor immunohistochemistry. No prognostic significance was found for chromosome-17 aneusomy. Conclusions: Low-level copy gains of HER2 define a biologically distinct subpopulation of Barrett s cancer patients. Importantly, these subtle copy number changes are not reliably detected by standard FISH in thin (4 Am) tissue sections, highlighting a thus far unrecognized weakness in HER2 FISH testing. These results should be taken into account for accurate evaluation of biomarkers by FISH and for HER2 FISH testing in tissue sections. Significant strides continue to be made in the treatment of patients with Barrett s cancer (Barrett s esophagus associated adenocarcinoma), which is now the most common esophageal cancer and which incidence is increasing faster than that of Authors Affiliations: 1 Institute of Pathology and 2 Institute of Molecular Radiation Biology, GSF-National Research Center for Environment and Health, Neuherberg, Germany; 3 Institute of Pathology, University Hospital Freiburg, Freiburg, Germany; 4 Department of Surgery, Klinikum Rechts der Isar and 5 Institute of Pathology, Technical University Munich, Munich, Germany; 6 Department of Surgery, University Hospital Salzburg, Salzburg, Austria; and 7 Kirchhoff-Institute of Physics, University of Heidelberg, Heidelberg, Germany Received 2/27/07; revised 5/18/07; accepted 6/14/07. Grant support: Deutsche Krebshilfe grant AZ Si 3. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with18 U.S.C. Section1734 solely to indicate this fact. Note: S. Rauser and R. Weis contributed equally to this work and share first authorship. Requests for reprints: AxelWalch, Institute of Pathology, GSF-National Research Center for Environment and Health, Ingolstaedter Landstrahe1, Neuherberg, Germany. Phone: ; Fax: ; axel.walch@ gsf.de. F 2007 American Association for doi: / ccr any other malignancy in the United States (1 3). At this time, early detection and complete surgical resection are the surest ways to cure esophageal cancer (3). Thus, new therapeutic targets and better prognostic markers for patient stratification are needed. Accurate determination of the status of HER2 in cancer provides significant insight into patient prognosis and may also inform selection of chemotherapeutic treatments. The effect of analyzing HER2 status by either fluorescence in situ hybridization (FISH) or immunohistochemistry has been investigated and also reviewed in extensive meta-analyses, supporting that FISH provides a more powerful prognostic indicator (4 7). This prompted us to investigate the genomic basis of HER2 expression and its prognostic implication in a cohort of Barrett s cancer patients. However, similar to immunohistochemistry methods, not all FISH methods are alike. To date, most FISH studies for standard HER2 testing of paraffinembedded tissue have been done and evaluated on thin (4 Am) sections by visual signal counting according to established standard procedures (8, 9). Although this standard thin-section technique is relatively easy to analyze, there are limitations with this approach. Most importantly, incomplete nuclei as a result of truncation as well as overlapping cells and/or signals Clin Cancer Res 2007;13(17) September 1, 2007

2 Imaging, Diagnosis, Prognosis Table 1. Experimental findings of FISH for HER2 and centromere-17 analyzed by thick-section (16 Am) threedimensional FISH (image-based signal evaluation), standard thin-section (4 Am) FISH (visual signal evaluation), and by HER2 immunohistochemistry in correlation with clinical and histopathologic data of investigated Barrett s cancer patients HER2 Mean gene copy number Three dimensional FISH (16-Mm sections), n = 124 HER2/CEP17 Ratio < z6.0 < z2.0 No. patients (%) 25 (20.2) 74 (59.7) 12 (9.7) 13 (10.5) 27 (21.0) 53 (42.7) 23 (18.5) 21 (16.9) Clinicopathologic data pt category pt 1 16 (12.9) 31 (25.0) 3 (2.4) 5 (4.0) 19 (15.3) 21 (16.9) 8 (6.5) 7 (5.6) pt 2 4 (3.2) 18 (14.5) 2 (1.6) 3 (2.4) 1 (0.8) 13 (10.5) 9 (7.3) 4 (3.2) pt 3 5 (4.0) 25 (20.2) 7 (5.6) 5 (4.0) 7 (5.6) 19 (15.3) 6 (4.8) 10 (8.1) Lymph node metastasis pn 0 18 (14.5) 42 (33.9) 4 (3.2) 9 (7.3) 20 (16.1) 28 (22.6) 13 (10.5) 12 (9.7) pn 1 7 (5.6) 32 (25.8) 8 (6.5) 4 (3.2) 7 (5.6) 25 (20.2) 10 (8.1) 9 (7.3) Distant metastasis M 0 25 (20.2) 67 (54.0) 11 (8.9) 11 (8.9) 26 (21.0) 49 (39.5) 21 (16.9) 18 (14.5) M 1 0 (0.0) 7 (5.6) 1 (0.8) 2 (1.6) 1 (0.8) 4 (3.2) 2 (1.6) 3 (2.4) NOTE: Values display the number of patients categorized into the corresponding scoring classes for mean HER2 gene copies (<2.5, z2.5-<4.0, z4.0-<6.0, and z6.0), HER2-to-chromosome-17 ratio (<1.1, z1.1-<1.5, z1.5-<2.0, and z2.0), and HER2 protein expression (0, 1+, 2+, and 3+). Abbreviation: HER2/CEP17, HER2-to-chromosome-17 ratio. inherent in tissue sections interfere with accurate signal scoring of individual nuclei, thereby decreasing the accuracy of FISH in detection of the actually present signal number (10 14). Although this weakness of FISH is well known, thus far, less attention has been drawn on these effects for accurate evaluation of biomarkers by FISH and for HER2 FISH testing in tissue sections. Recent advantages in three-dimensional microscopic imaging technologies have helped to Table 2. FISH and immunohistochemistry findings in correlation with clinicopathologic variables, disease-free and overall survival Univariate analysis Variable Three-dimensional FISH (16-Am sections), n = 124 HER2 HER2/CEP17 pt pn M G R DFS OS Multivariate analysis Variable P HR 95% CI P HR 95% CI P HR HER * (0.098) (1.8) ( ) (0.13) (1.6) ( ) (0.65) (-*) PT (0.14) (1.3) ( ) (0.14) (1.3) ( ) (0.20) (1.3) PN (0.0051) (2.6) ( ) (0.0049) (2.6) ( ) (0.0075) (2.7) R (0.0005) (3.0) ( ) (0.0004) (3.1) ( ) (0.0003) (3.3) NOTE: Statistically significant P values are in bold. Univariate analysis and results of proportional hazards models for disease-free survival and for overall survival; results for overall survival are set in brackets. Risk ratios (hazard ratios) and their lower and upper 95% confidence limits apply for the units of measure in question. Abbreviations: DFS, disease-free survival; OS, overall survival; HR, hazards ratio. *Not different from 1.0. Clin Cancer Res 2007;13(17) September 1,

3 HER2 Low-Level Copy Gain in Barrett s Cancer Table 1. Experimental findings of FISH for HER2 and centromere-17 analyzed by thick-section (16 Am) threedimensional FISH (image-based signal evaluation), standard thin-section (4 Am) FISH (visual signal evaluation), and by HER2 immunohistochemistry in correlation with clinical and histopathologic data of investigated Barrett s cancer patients (Cont d) Standard FISH (4-Mm sections), n = 107 Immunohistochemistry, n = 123 HER2 HER2/CEP17 HER2 Mean gene copy number Ratio Score < z6.0 < z (80.4) 6 (5.6) 5 (4.7) 10 (9.3) 35 (32.7) 40 (37.4) 18 (16.8) 14 (13.1) 85 (69.1) 17 (13.8) 9 (7.3) 12 (9.8) 38 (35.5) 1 (0.9) 2 (1.9) 2 (1.9) 16 (15.0) 15 (14.0) 8 (7.5) 4 (3.7) 36 (29.3) 11 (8.9) 5 (4.1) 3 (2.4) 19 (17.8) 2 (1.9) 0 (0.0) 3 (2.8) 5 (5.7) 12 (11.2) 3 (2.8) 4 (3.7) 19 (15.4) 3 (2.4) 2 (1.6) 3 (2.4) 29 (27.1) 3 (2.8) 3 (2.8) 5 (4.7) 14 (13.1) 13 (12.1) 7 (6.5) 6 (5.6) 30 (24.4) 3 (2.4) 2 (1.6) 6 (4.9) 47 (43.9) 2 (1.9) 2 (1.9) 6 (5.6) 21 (19.6) 22 (20.6) 6 (5.6) 8 (7.5) 47 (38.2) 12 (9.8) 8 (6.5) 6 (4.9) 39 (36.4) 4 (3.7) 3 (2.8) 4 (3.7) 14 (13.1) 18 (16.8) 12 (11.2) 6 (5.6) 38 (30.9) 5 (4.1) 1 (0.8) 6 (4.9) 78 (72.9) 6 (5.6) 5 (4.7) 9 (8.4) 32 (29.9) 39 (36.4) 14 (13.1) 13 (12.1) 77 (62.6) 14 (11.4) 9 (7.3) 11 (8.9) 8 (7.5) 0 (0.0) 0 (0.0) 1 (0.9) 3 (2.8) 1 (0.9) 4 (3.7) 1 (0.9) 8 (6.5) 1 (0.8) 0 (0.0) 1 (0.8) circumvent these problems leading to an increased sensitivity for signal scoring within thick-section (>10 Am) tissue specimen (10 16). In this study, we compared standard laboratory FISH on thin (4 Am) sections to a three-dimensional image-based analysis on thick (16 Am) sections (three-dimensional FISH) for HER2 FISH testing. Atissue microarray (TMA) cohort of 124 Barrett s cancer patients was analyzed by standard FISH and threedimensional FISH for HER2 and chromosome-17 as well as for expression of p185 HER2 by immunohistochemistry. Correlations with follow-up and histopathologic data were tested. Accordingly, paraffin-embedded cells of varying section thickness (2-20 Am, interval of 2 Am) were analyzed referring to the effect of nuclear truncation on the accuracy for HER2 testing. In doing so, we intended to find out which methods accurately measure HER2 status as validated by outcome of patients with Barrett s cancer. Materials and Methods Patient selection and tissue samples All patients (n = 124) underwent primary surgical resection without chemotherapy or radiotherapy at the Department of Surgery, Klinikum Rechts der Isar, Technical University Munich. All cases had adenocarcinomas of the distal esophagus (Barrett s cancer) associated with histopathologically identified Barrett s esophagus (according to WHO Table 2. FISH and immunohistochemistry findings in correlation with clinicopathologic variables, disease-free and overall survival (Cont d) Standard FISH (4-Am sections), n = 107 Immunohistochemistry, n = 123 HER2 HER2/CEP17 HER % CI P HR 95% CI P HR 95% CI -* * -* (-*) (0.34) (1.3) ( ) (0.125) (1.2) ( ) ( ) (0.15) (1.4) ( ) (0.124) (1.4) ( ) ( ) (0.0089) (2.6) ( ) (0.006) (2.5) ( ) ( ) (0.0006) (3.1) ( ) (0.0002) (3.3) ( ) Clin Cancer Res 2007;13(17) September 1, 2007

4 Imaging, Diagnosis, Prognosis 2000; ref. 17). Data were acquired with approval from the ethics committee of the Technical University Munich. Survival analyses were calculated from all 124 patients. The mean age at surgery was years and maximum follow-up time was months (median for disease-free survival, 31.2 months; median for overall survival, 33.1 months). Tissue microarrays TMAs were constructed by sampling three tumor tissue cores (1.0 mm in diameter) from each paraffin-embedded tissue block using the technique pioneered by Kononen et al. (18). Serial sections were cut and transferred to adhesive slides using the Paraffin Tape-Transfer System (Instrumedics). Cell paraffin block preparation and sectioning T47D cell line (American Type Culture Collection) was applied in a model experiment (a) to study the effect of nuclear truncation on the accuracy for HER2 FISH testing and (b) to determine the optimal section thickness for three-dimensional FISH in Barrett s cancer. This cell line is known as tetraploid with four gene copies for HER2 copy and four copies for chromosome-17 (19). The cells were maintained according to the recommendations of the manufacturer and a paraffin block was prepared as described by Crockett et al. (20). Sections of varying thickness (2-20 Am, interval of 2 Am) were cut and placed on slides. Fluorescence in situ hybridization Acommercially available assay with fluorescence-labeled locusspecific DNAprobes for HER2 and chromosome-17 centromeric a-satellite (Chrombios) was hybridized on the specimen according to a protocol described previously (21, 22). The hybridization specificity of the probes was tested in metaphase spreads and lymphocytes served as internal controls in tumor tissue samples. FISH signal evaluation Visual-based signal evaluation within 4 mm TMA sections. Signal evaluation within standard 4 Am TMAsections was done by visual counting using an epifluorescence microscope (Zeiss Axioplan 2, Carl Zeiss Microimaging GmbH) according to standard procedures as recommended in literature (8, 9). At least 50 invasive tumor cells per case were selected randomly, whereas only cells with a minimum of one signal for HER2 gene and centromere-17 were chosen, and the mean was calculated. Image-based signal evaluation within 16-mm (thick) TMA sections and within T47Dcell line (three-dimensional FISH). Copy numbers of HER2 gene and centromere-17 within 16 Am TMAsections and T47D cell line sections (2-20 Am) were assessed by optical sectioning and three-dimensional imaging (10, 12, 15). To obtain a three-dimensional data set, image stacks with an interval of 500 nm between two subsequent images were acquired using an Apotome, which was implemented into the setup of a Zeiss Axioplan 2 epifluorescence microscope. The microscope was equipped with a C-Apochromat 63/NA1.2 W objective and an AxioCam b/w charge-coupled device camera. Signal evaluation of HER2 and centromere-17 in threedimensional data set was done by applying the AxioVision software (release 4.5) as described previously (12, 16). Signals were identified by three-dimensional visualization and scrolling through the optical sections. Signals were assessed only in obviously intact (i.e., not truncated cell nuclei with at least one signal for HER2 and centromere-17). Aminimum of 50 tumor cell nuclei per case was counted. FISH scoring criteria. FISH scoring for mean HER2 signal number was applied according to published criteria (6, 8, 9, 23) and four categories were determined: mean HER2 signal numbers <2.5, z2.5 to 4.0, z4.0 to 6.0, and z6.0. HER2 copies z6.0 were designated as highlevel HER2 amplification. The HER2 level was also determined as ratio of HER2-to-chromosome-17 within the following four scoring classes: mean ratio <1.1, z1.1 to 1.5, z1.5 to 2.0, and z2.0. HER2-to-chromosome-17 ratios z2.0 were designated as HER2 amplification. Immunohistochemistry The expression levels of HER2 oncoprotein were analyzed using the HercepTest kit according to the manufacturer s instructions (DAKO). Tumors were classified as 0, 1+, 2+, or 3+ as recommended (9). Freshly cut 5-Am TMAsections and the cell line control slides provided by the manufacturer were stained. Statistical analysis Associations between molecular variables and pt and G were examined by Spearman s rank correlation, whereas Mann-Whitney test was used for two-valued variables, such as pn, M, and R. Disease-free and overall survival rates were calculated according to the Kaplan-Meier method, including median and 95% confidence interval (95% CI), and tested with the log-rank m 2 value. Multivariate survival analyses were determined using Cox proportional hazards regression for each of the HER2 variables together with the clinical variables pt, pn, and R, including risk ratios and 95% CI. Correlation analyses were done using Spearman s rank test. Calculations were done by use of the statistical data analysis system R (packages stats and survival ). 8 All tests were two sided, and P values <0.05 were considered statistically significant. Results Three-dimensional FISH within thick (16 mm) tissue sections: HER2 gene copy number/her2-to-chromosome-17 ratios and clinicopathologic correlations. HER2 gene amplification (z6.0 signals) was found in 10.5% of patients. The majority of the analyzed patients revealed low-level copy number changes for HER2 (z signals; 59.7%). Amean signal number of HER2 <2.5 was observed in 20.2% of the analyzed patients (Table 1). There was a statistically significant correlation between HER2 and pt (P = 0.041) but none for pn, M, G, and R (Table 2). Mean HER2 gene copy number was significantly associated with disease-free survival (P = 0.017) but not with overall survival (P = 0.052). In survival analysis, the subgroup with low-level copy number gain (z signals) was as aggressive as the group with HER2 gene amplification (z6.0 signals; Fig. 1A). Among the most important established prognostic factors (pt, pn, and R), multivariate Cox regression analysis revealed HER2 as an independent prognostic factor for disease-free survival (relative risk, 2.1; 95% CI, ; P = 0.033) but not for overall survival (Table 2). HER2 gene amplification, as defined by the ratio of HER2- to-centromere-17 z2.0, was found in 16.9% of patients; 61.2% showed a ratio z1.1 to 2.0 and 21.0% displayed a ratio <1.1 (Table 1). HER2-to-chromosome-17 ratio was also statistically associated with pt (P = ) and disease-free survival (P = 0.044), but there was no correlation for pn, M, G, and R and overall survival (P = 0.053; Table 2). In survival analysis, the subgroup with low-level copy number gain (ratio, z ) was as aggressive as the group with HER2 gene amplification (ratio, z2.0; Fig. 1B). Centromere-17 copy number on its own was not related to disease-free survival (P = 0.59) and overall survival (P = 0.75), 8 Clin Cancer Res 2007;13(17) September 1,

5 HER2 Low-Level Copy Gain in Barrett s Cancer Fig. 1. Kaplan-Meier curves showing diseasefree survival of patients with Barrett s cancer evaluated by image-based three-dimensional FISH within 16-AmTMA sections (A and B) compared with standard FISH within 4-AmTMA sections (C and D). Data were analyzed according to mean HER2 gene copy number (A and C) and HER2-to-chromosome-17 ratio (HER2/CEP17; B and D). Statistical significance of differences between groups was evaluated with the log-rank m 2 test and a P value of <0.05 was considered significant. Time is shown in months. indicating that aneusomy of chromosome-17 did not show prognostic significance. Similarly, multivariate Cox regression analysis did not display HER2-to-chromosome-17 ratio as a significant predictor, neither for disease-free survival nor for overall survival (Table 2). Standard FISH within thin (4 mm) tissue sections: HER2 gene copy number/her2-to-chromosome-17 ratios by visual counting and clinicopathologic correlations. HER2 gene amplification (z6.0 signals) was found in 9.3% of patients. Low copy number changes (z signals) were present for 5.6% patients. The vast majority of cases (80.4%) displayed an average signal number of <2.5 signals (Table 1). Neither HER2 mean copy number nor HER2-to-centromere- 17 ratio was associated with pt, pn, M, G, and R, as well there was no statistically significant correlation with patients diseasefree survival (Fig. 1C and D) and overall survival (Table 2). Similarly, centromere-17 copy number was not related with patients clinical outcome (disease-free survival, P = 0.36; overall survival, P = 0.23). As there was no significance in univariate analysis, multivariate Cox regression analysis did not show HER2 to be an independent prognostic marker (Table 2). Sectioning effects bias HER2 signal evaluation in the low-level copy interval. In 4 Am T47D sections, obviously all nuclei were truncated, whereas, in 16 Am sections, the majority of nuclei (80%) were intact (Fig. 2A). The mean HER2 gene copy number within 4 Am and 16 Am T47D sections was calculated with 2.1 F 0.12 and 3.98 F 0.03, respectively (Fig. 2B). The detection of the true HER2 copy number of 4 depended on section thickness >12 Am, whereas, in 4-Am sections, the true signal number was underestimated (mean HER2 copy number, 2.1 F 0.12). Accordingly, only 6% of analyzed nuclei within 4-Am sections exhibited the total number of four HER2 signals, whereas within 16 Am sections, almost all (i.e., 96%) nuclei were detectable bearing four HER2 copies (Fig. 2C). Within sections of 2 to 8 Am, a mixture of 1, 2, 3, or 4 signals could be evaluated in individual nuclei. In contrast, within sections z12 Am, predominantly, nuclei with three and four HER2 copies Clin Cancer Res 2007;13(17) September 1, 2007

6 Imaging, Diagnosis, Prognosis Fig. 2. Influence of section thickness on accurate HER2 signal evaluation in paraffin-embeddedt47d cells (true signal number is four copies for HER2). Sections of different thickness (2-20 Am, interval of 2 Am) were analyzed by image-based threedimensional FISH for HER2 gene copy number. A, increasing proportion of intact nuclei within rising section thickness (white columns, truncated nuclei; black columns, intact nuclei). Note, in standard thin (4 Am) sections, obviously, all nuclei were truncated, whereas, in thick (16 Am) sections, the majority of nuclei (80%) were intact. B, points, mean HER2 signal number increased with rising section thickness; bars, SE. The detection of the actual HER2 copy number of 4 depends on section thickness >12 Am, whereas, in standard 4-Am sections, the true signal number of four copies is underestimated (mean HER2 copy number, 2.1 F 0.12). C, distribution of scored HER2 signals in individual cell nuclei.within sections V8 Am, a mixture of 1, 2, 3, and 4 signals was evaluated, whereas the true number of 4 signals remained constant in sections z16 Am. were present, whereas the maximum of 4 signals remained constant in sections z14 Am (Fig. 2C). Figure 3 shows sectioning effects on FISH signal evaluation in tissue sections of Barrett s cancer. Comparison between three-dimensional FISH on thick (16 mm) sections and standard FISH analyses on thin (4 mm) sections. Both FISH methods identified almost the same proportion of Barrett s cancer patients with HER2 gene amplification (i.e., HER2, z6.0 signals; HER2-to-chromosome-17 ratio, z2.0) as detected by three-dimensional FISH (10.5% and 16.9%) or by standard FISH (9.3% and 13.1%). However, there was a difference within the other scoring classes. In detail, 80.4% of cases analyzed within thin (4 Am) sections showed HER2 gene copies <2.5, whereas this group consisted of only 20.2% in thick (16 Am) sections when analyzed by three-dimensional FISH. Accordingly, the group showing lowlevel copy number gain (z signals) as detected by standard FISH accounted to 5.6%, whereas this low-level copy group increased to 59.7% as detected by three-dimensional FISH. There was a correlation of mean HER2 signal number evaluated within thin (4 Am) and thick (16 Am) sections (Spearman rank correlation r s = 0.43; P < ). However, particularly in the interval of z2.5 to 6.0 signals, both methods did not correlate (r s =0.20; P = 0.095) and three-dimensional FISH detected 1.9-fold higher values than those that had been assessed by standard FISH (Fig. 4). HER2 oncoprotein expression and clinicopathologic correlations. Overexpression of HER2 protein indicated by a score of 3+ was observed in 9.8% of patients. Ascore of 2+ was Clin Cancer Res 2007;13(17) September 1,

7 HER2 Low-Level Copy Gain in Barrett s Cancer observed in 7.3% of patients, whereas a score of 1+ or 0 was observed in 13.8% and 69.1% of patients, respectively. We observed a statistically significant inverse correlation between HER2 protein expression and tumor grading (P = 0.013), whereas differentiated (G 1 and G 2 ) tumors predominantly showed overexpression of HER2 protein. No significant association with other clinicopathologic features (pt, pn, M, and R) was found as well there was no prognostic effect on disease-free and overall survival (Table 2). Discussion By careful quantification of the exact copy numbers of HER2 and chromosome-17, comparing standard FISH on thin (4 Am) Fig. 3. Tissue sectioning effects on accurate FISH signal evaluation. A and B, three-dimensional visualization of microscopic image stacks within 4 Am tissue section (A)and 16 Am tissue section (B) of the very same Barrett s cancer case. Corresponding to Fig. 2A in standard thin (4 Am) sections, obviously, all nuclei were truncated, whereas, in thick (16 Am) sections, the majority of nuclei were intact. C to F, tissue sectioning effects on accurate signal evaluation for a HER2 nonamplified case (C and D) and a HER2-amplified case (E and F) of Barrett s cancer. Each of the two rows displays the very same case of Barrett s cancer. FISH for HER2 gene (red signals) and centromere-17 (green signals) is shown in comparison within a thin (4 Am) section (column1, stabdard FISH) and a thick (4 Am) section (column 2, three-dimensional FISH). Image stacks were transferred into a projection. Case 27 (E and F) shows that high-level HER2 amplification is detectable by both FISH techniques, standard FISH (E) and three-dimensional FISH (F). Unlike to HER2 amplification, case 104 (C and D) shows that the detection of low-level copy gain is inconsistent by standard FISH on 4 Am sections (C) compared with three-dimensional FISH on 16 Am sections (D). Although in case 104, a low-level copy gain is obviously present (D), the true copy number is masked due to nuclear truncation in standard 4 Am sections (C), possibly leading to a false classification as normal Clin Cancer Res 2007;13(17) September 1, 2007

8 Imaging, Diagnosis, Prognosis Fig. 4. Correlation of mean HER2 gene copy number evaluated by image-based three-dimensional FISH (16 Am sections) and by standard FISH (4 Am sections) in tissue sections of all investigated Barrett s cancer cases. Apotome-based signal evaluation within 16 Am sections detected 1.9-fold higher values than corresponding visual evaluation within 4 Am sections. Particularly in the interval z2.5 to <6.0 HER2 signals, both methods did not correlate (Spearman rank correlation r s =0.20;P = 0.095). sections and image-based three-dimensional approach on thick (16 Am) sections (three-dimensional FISH), we have shown thus far unrecognized weakness in FISH, a current standard for evaluation of HER2 status. Specifically, we found in our patient cohort that low-level copy number gain (z signals) of HER2 is not reliably detectable by standard FISH analysis in thin (4 Am) tissue sections. Importantly, such subtle copy number changes of HER2 occur frequently and define a biologically distinct subpopulation as unfavorable for patient outcome as HER2 gene amplification in Barrett s cancer (Fig. 1). Albeit FISH is a sensitive quantitative method appropriate for assessment of the full dynamic range of HER2 gene copy number changes, most studies use this technique rather than a binary approach for the detection of the extreme top signal number (i.e., the presence or absence of gene amplification). Hence, numerous reports have been shown the reliability of HER2 gene amplification detection by the well-established thin-section (4 Am) FISH technique (8, 9). However, thus far, less attention has been drawn on effects of tissue sectioning for standard HER2 FISH testing. Our data indicate that high-level HER2 amplification (HER2 signal number, z6.0; HER2-to-chromosome-17 ratio, z2.0) is reliably detectable by both approaches (thin-section versus thick-section FISH technique; Table 1). Unlike, it has not been shown thus far, whether the standard thin-section FISH technique reliably detects low-level copy number changes and the prognostic and therapeutic significance of low-level copy number gains is ambiguous. Such uncertainty might also contribute to the recently published considerable variation in interpretation of results for breast cancer with low-level HER2 amplification (24). In contrast to detection of HER2 amplification, we observed a striking variation for the detection of low-level copy number gain (HER2 signal number, z ) in 4-Am sections (5.6%) compared with 16 Am sections (59.7%; Table 1). In other words, a large proportion of tumors with slight copy number increase in the low-level group detected by thick-section technique (three-dimensional FISH) would not have been recognized in standard HER2 FISH testing and hence would have been classified as normal (Fig. 3C and D). Further evidence comes from our experiments investigating the influence of section thickness on FISH signal evaluation in a paraffin-embedded cell line with four gene copies for HER2 (19). In standard thin-section FISH technique, obviously, all tumor cell nuclei are truncated due to tissue sectioning (Figs. 2 and 3). This effect is self-explanatory as the mean diameter of tumor cell nuclei (10 Am) is more than twice of the standard section thickness (4 Am), resulting in a loss of at least 40% of the nuclear volume. Hence, nuclear truncation decreases the accuracy of FISH in detection of the actually present signal number as published repeatedly (10 14). Correspondingly, our data indicate a nonlinear correlation between nuclear truncation and mean signal number, leading to a bias particularly affecting the low-level copy interval in thin (4 Am) sections (Fig. 2). Beyond these technical considerations, our data may also have a biological aspect. Thus far, such adverse effects of lowlevel gain on patient outcome as observed in our series has not been shown yet for HER2 gene copy number but for low expression of HER2 protein in breast cancer (25 28). Corresponding to our observations, these reports have shown that more sensitive assays (i.e., AQUA method or radioimmunohistochemistry), which increased the dynamic range of HER2 protein detection, could identify patient subgroups with low or even normal expression of HER2 protein being as unfavorable for survival as strong overexpression (25 28). However, it is unclear, thus far, if low-level copy number gain actually leads to elevated expression of HER2 protein. In our series, the patient subgroup with low-level copy number gain was not definable by standard immunohistochemistry. This may be explained by the low sensitivity of this standard approach, which is unable to detect slightly elevated expression levels if actually present (29). Previous studies examining HER2 status in Barrett s cancer observed a prevalence of HER2 protein overexpression or gene amplification in Barrett s cancer ranging from 0% to 83% (21, 30 40). Lack of agreement among these studies may be related to the differing sensitivities and specificities of the assay methods used to assess HER2 as a prognostic marker. Several authors suggested that the accurate evaluation of HER2 may be useful as a biomarker of progression from intestinal metaplasia to intraepithelial neoplasia in carcinogenesis of Barrett s esophagus (30, 31). Because most moleculargenetic changes are rather subtle in precursor lesions, this research field might particularly benefit from sensitive methods such three-dimensional FISH to detect subtle signal changes. Importantly, we did not find prognostic significance for chromosome-17 aneusomy in our Barrett s cancer cohort. Clinically, it is uncertain, thus far, whether an increase in HER2 copy number alone or an increase of HER2 copies relative to copies of chromosome-17 is more useful in predicting outcome. According to our findings, the results of a recent report in breast cancer suggest that increased HER2 gene dosage may be the most important determinant of HER2 Clin Cancer Res 2007;13(17) September 1,

9 HER2 Low-Level Copy Gain in Barrett s Cancer gene expression, whereas that resulting from polysomy 17 alone is rather unlikely to significantly contribute to HER2 overexpression (41). From a clinical perspective, response to Herceptin has largely been seen in HER2 high expressers or HER2-amplified cases. Although Barrett s cancer patients with low-level gene copy gain of HER2 are unlikely to respond to Herceptin, they may benefit from more aggressive traditional chemotherapy. HER2 status might be incorporated into a clinical decision, along with other prognostic factors, about whether to give any adjuvant systemic therapy. HER2 status may also to be predictive for either resistance or sensitivity to different types of chemotherapeutic agents. Thus, the ability to accurately distinguish between low-level gene copy gains and high-level gene amplification of HER2 by three-dimensional FISH does not only have prognostic value but may also help in the development and evaluation of new therapeutics targeted to treat this patient subpopulation. In summary, this study highlights a thus far unrecognized weakness in standard HER2 FISH testing, specifically referring to the low-level copy interval, which could not reliably be detected in standard thin (4 Am) tissue sections in our study. Importantly, these subtle copy number changes of HER2 defined a considerable and biologically distinct subpopulation in Barrett s cancer. These results should be taken into account for accurate evaluation of biomarkers by FISH and for HER2 FISH testing in tissue sections. Acknowledgments We thank Lieselotte Bokla, Ulrike Buchholz, Eleonore Samson, and AndreasVoss for excellent technical assistance. References 1. Wild CP, Hardie LJ. Reflux, Barrett s oesophagus, and adenocarcinoma: burning questions. Nat Rev Cancer 2003;3:676 ^ PaulsonTG, Reid BJ. Focus on Barrett s esophagus and esophageal adenocarcinoma. Cancer Cell 2004; 6:11^6. 3. DeMeester SR. Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment. AnnSurgOncol2006;13:12^ Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist 1998;3:237^ Mitchell MS, Press MF. The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer. Semin Oncol 1999;26:108^ Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000;18:3651^ Ross JS, FletcherJA, Bloom KJ, et al. Targeted therapy in breast cancer: the HER-2/neu gene and protein. MolCellProteomics2004;3:379^ Hicks DG,Tubbs RR. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Hum Pathol 2005;36:250^ Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.jclinoncol2007;25:118^ Hopman AH, van Hooren E, van de Kaa CA, Vooijs PG, Ramaekers FC. Detection of numerical chromosome aberrations using in situ hybridizationinparaffin sections of routinely processed bladder cancers. Mod Pathol 1991;4:503^ Thompson CT, LeBoit PE, Nederlof PM, Gray JW. Thick-section fluorescence in situ hybridization on formalin-fixed, paraffin-embedded archival tissue provides a histogenetic profile. Am J Pathol 1994;144: 237 ^ Aubele M, Zitzelsberger H, Szucs S, et al. Comparative FISH analysis of numerical chromosome 7 abnormalities in 5-micron and 15-micron paraffinembedded tissue sections from prostatic carcinoma. Histochem Cell Biol 1997;107:121^ D Alessandro I, Zitzelsberger H, Hutzler P, et al. Numerical aberrations of chromosome 7 detected in 15 microns paraffin-embedded tissue sections of primary cutaneous melanomas by fluorescence in situ hybridization and confocal laser scanning microscopy. J Cutan Pathol 1997;24:70^ Chin K, de Solorzano CO, Knowles D, et al. In situ analyses of genome instability in breast cancer. Nat Genet 2004;36:984 ^ Maierhofer C, Gangnus R, Diebold J, Speicher MR. Multicolor deconvolution microscopy of thick biological specimens. Am JPathol 2003;162:373^ WiechT,Timme S, Riede F, et al. Human archival tissues provide a valuable source for the analysis of spatial genome organization. Histochem Cell Biol 2005; 123:229 ^ Werner M, Flejou JF, Hainaut P, et al. Adenocarcinoma of the oesophagus In World Health Organization Classification of Tumours. In: Hamilton SR, Aaltonen LA, editors. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press; p. 20 ^ Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844 ^ Lyon E, Millson A, Lowery MC, Woods R, Wittwer CT. Quantification of HER2/neu gene amplification by competitive pcr using fluorescent melting curve analysis. Clin Chem 2001;47:844^ CrockettDK,LinZ,VaughnCP,LimMS,Elenitoba- Johnson KS. Identification of proteins from formalinfixed paraffin-embedded cells by LC-MS/MS. Lab Invest 2005;85:1405 ^ WalchA,SpechtK,BinkK,etal.Her-2/neu gene amplification, elevated mrna expression, and protein overexpression in the metaplasia-dysplasia-adenocarcinoma sequence of Barrett s esophagus. Lab Invest 2001;81:791 ^ Walch A, Bink K, Hutzler P, et al. Sequential multilocus fluorescence in situ hybridization can detect complex patterns of increased gene dosage at the single cell level in tissue sections. Lab Invest 2001;81: 1457 ^ Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002;20:3095 ^ Persons DL,Tubbs RR, Cooley LD, et al. HER-2 fluorescence in situ hybridization: results from the survey program of the College of American Pathologists. Arch Pathol Lab Med 2006;130:325 ^ Koscielny S, Terrier P, Daver A, et al. Quantitative determination of c-erbb-2 in human breast tumours: potential prognostic significance of low values. Eur J Cancer 1998;34:476^ Camp RL, Dolled-Filhart M, King BL, Rimm DL. Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res 2003;63:1445 ^ McCabeA,Dolled-FilhartM,CampRL,RimmDL. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. JNatl Cancer Inst 2005;97:1808^ Tovey S, Reeves J, Stanton P, Ozanne B, Bartlett J, Cooke T. Low expression of HER2 protein in breast cancer is biologically significant. J Pathol 2006;210: 358^ Rimm DL.What brown cannot do for you. Nat Biotechnol 2006;24:914^ Reichelt U, Duesedau P, Tsourlakis MCh, et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 2007;20:120 ^ Rossi E,Villanacci V, Bassotti G, et al. Her-2/neu in Barrett esophagus: a comparative study between histology, immunohistochemistry, and fluorescence in situ hybridization. Diagn Mol Pathol 2006;15: 125 ^ Walch A, Specht K, Braselmann H, et al. Coamplification and coexpression of GRB7 and ERBB2 is found in high grade intraepithelial neoplasia and in invasive Barrett s carcinoma. Int J Cancer 2004;112: 747 ^ Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001;19:554 ^ BrienTP, Odze RD, Sheehan CE, McKenna BJ, Ross JS. HER-2/neu gene amplification by FISH predicts poor survival in Barrett s esophagus-associated adenocarcinoma. Hum Pathol 2000;31:35^ Polkowski W, van Sandick JW, Offerhaus GJ, et al. Prognostic value of Lauren classification and c- erbb-2 oncogene overexpression in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol 1999;6:290^ Hardwick RH, Shepherd NA, Moorghen M, Newcomb PV, Alderson D. c-erbb-2 overexpression in the dysplasia/carcinoma sequence of Barrett s oesophagus. J Clin Pathol 1995;48:129^ NakamuraT, Nekarda H, Hoelscher AH, et al. Prognostic value of DNA ploidy and c-erbb-2 oncoprotein overexpression in adenocarcinoma of Barrett s esophagus. Cancer 1994;73:1785^ Flejou JF, Paraf F, Muzeau F, et al. Expression of c- erbb-2 oncogene product in Barrett s adenocarcinoma: pathological and prognostic correlations. J Clin Pathol 1994;47:23^ Al-Kasspooles M, MooreJH, Orringer MB, Beer DG. Amplification and over-expression of the EGFR and erbb-2 genes in human esophageal adenocarcinomas. Int J Cancer1993;54:213^ JankowskiJ, Coghill G, Hopwood D,Wormsley KG. Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus. Gut1992;33:1033^ Downs-Kelly E,Yoder BJ, Stoler M, et al. The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mrna in situ hybridization study. Am J Surg Pathol 2005;29:1221 ^ Clin Cancer Res 2007;13(17) September 1, 2007

10 Significance of HER2 Low-Level Copy Gain in Barrett's Cancer: Implications for Fluorescence In situ Hybridization Testing in Tissues Sandra Rauser, Roland Weis, Herbert Braselmann, et al. Clin Cancer Res 2007;13: Updated version Access the most recent version of this article at: Cited articles Citing articles This article cites 40 articles, 10 of which you can access for free at: This article has been cited by 2 HighWire-hosted articles. Access the articles at: alerts Sign up to receive free -alerts related to this article or journal. Reprints and Subscriptions Permissions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org. To request permission to re-use all or part of this article, use this link Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.